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ABSTRACT 
 Clofibrate is a commercially available chemical that has been found to induce increased 
cell division in the hepatocytes of rodents. Previous experiments in our lab have investigated the 
use of clofibrate to bypass the need for nuclear targeting in non-viral gene delivery systems, since 
the large size of the gene delivery vector limits its ability to enter the nucleus of hepatocytes. We 
decided to replicate these experiments, with the intention of seeing higher levels of gene expression 
by using targeted DNA nanoparticles that contained additional targeting for mice hepatocytes. 
Mice were dosed with corn oil, clofibrate, clofibrate and non-targeted DNA nanoparticle, or 
clofibrate and targeted DNA nanoparticle over the course of a 5-day clofibrate dosing protocol. 
Body weight gain, liver weight gain, and levels of luciferase gene expression was compared across 
treatment groups. It was found that only the treatment group dosed with non-targeted DNA 
nanoparticles exhibited a 10-fold increase in gene expression compared to the control group (p = 
0.0108). Therefore, we decided to further explore this result by determining if a dose-dependent 
response would be seen from non-targeted DNA nanoparticles over the course of a 14-day 
clofibrate dosing protocol. Mice were dosed with clofibrate, clofibrate and 10 g non-targeted 
DNA nanoparticle, or clofibrate and 100 g non-targeted DNA nanoparticle with changes in body 
weight, liver weight, and luciferase gene expression being recorded. The data suggested that non-
targeted DNA nanoparticles did not exhibit a dose-dependent response in luciferase gene 
expression when dosed in the presence of clofibrate.   
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AN INTRODUCTION TO GENE THERAPY 
 Hemophilia is a rare, genetic disorder that affects an estimated 400,000 people worldwide.1 
This disorder prevents the blood from clotting normally, because the liver is unable to produce 
functioning blood-clotting proteins (clotting factors). Therefore, bleeding cannot be stopped 
because a blood clot cannot form. Currently, hemophilia is treated by injecting the missing clotting 
factor into the bloodstream. A person with hemophilia that has a simple cut or scrape can be given 
this replacement therapy until the bleeding is stopped. However, individuals can suffer from 
internal bleeding, caused by something such as a bump to the knee or in severe cases, be due to 
spontaneous bleeding that occurs within the body. Internal, spontaneous bleeding is very difficult 
to detect and can have life-threatening complications. 
Gene therapy can provide an alternative solution for those with hemophilia. Rather than 
using a replacement therapy to treat the primary symptom, gene therapy can potentially treat the 
disorder itself. Gene therapy treats disease by introducing genetic material into cells. This would 
mean that for individuals with hemophilia, new DNA would be delivered to hepatocytes, thereby 
allowing for the continuous production of normal, functioning clotting factors without the need for 
replacement therapy.  
Gene therapy has the ability to treat several diseases using a variety of approaches. Viral 
gene therapy is one of these approaches, where an inactivated virus is used to deliver genetic 
material to cells. In December 2017, LUXTURNATM became the first FDA-approved prescription 
gene therapy, which uses a benign form of the adeno-associated virus (AAV) to treat inherited 
retinal disease.2 Unlike most viral gene therapies, which can be compromised by the potential for 
immunogenicity, LUXTURNATM is successful because the eyes are immune-privileged.2 Usually 
viral gene therapy can only be performed under in vitro conditions, where gene delivery takes 
place outside of a living organism, such as in a test tube or a cell culture dish. Viral gene therapy 
is difficult to use under in vivo conditions, because the living organism can develop an immune 
response to the viral delivery vector.  
Non-viral gene therapy provides an alternative method, because it is potentially non-
immunogenic when delivered under in vivo conditions. Rather than using a viral delivery vector, 
non-viral gene therapy utilizes natural and synthetic nanoparticles to deliver genetic material. In 
August 2018, ONPATTROTM became the first FDA-approved prescription non-viral gene therapy, 
with its ability to deliver small interfering ribonucleic acid (siRNA) to treat a rare, peripheral nerve 
disease.3 This genetic disorder is characterized by the buildup of amyloid proteins in peripheral 
nerves, the heart, and other organs. ONPATTROTM encases siRNA into a lipid nanoparticle, 
therefore allowing therapeutic levels of siRNA to be delivered to hepatocytes.3 Once it reaches the 
hepatocyte the siRNA is able to interfere with protein production, thereby reducing the 
accumulation of amyloid deposits.3  
 Despite its recent success, several obstacles still stand in the way of the application of non-
viral gene delivery to all diseases. One of the most significant barriers is delivering DNA to the 
nucleus, the site of DNA transcription that eventually leads to protein translation. Due to the large 
size of the non-viral delivery vector, only limited amounts of DNA can be actively transported into 
the nucleus. Consequently, DNA delivery and expression are often inefficient. Therefore, the focus 
of this thesis was to develop a non-viral delivery system that can deliver therapeutic levels of DNA 
to the nucleus.  
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CREATING THE NON-VIRAL DELIVERY VECTOR 
Packaging DNA  
DNA must be packaged into a nanoparticle in order to prevent metabolism and to promote 
entry into the hepatocyte. This process involves the chemical interaction between DNA and a 
peptide molecule. The structure of peptides offers several advantages when creating a DNA 
nanoparticle, including more precise and flexible chemical modifications, use in both in vivo and 
in vitro transfection, and a low molecular weight to avoid detection by the immune system.4 
Despite these advantages, the smaller size of peptides results in decreased DNA binding affinity.4 
Therefore, the peptide underwent chemical modification in order to restore binding affinity. 
First, several cysteine residues were added onto the terminal ends of the peptide.4 Then 
polyethylene glycol (PEG), an important polymer that aids in systemic delivery, was attached to 
one of these cysteine residues.4 The DNA nanoparticle remained PEGylated in circulation until it 
reached the hepatocyte.4 Once the nanoparticle entered the hepatocyte, the PEG layer dissociated 
and the nanoparticle could now better interact with the cell.4  
 
Primary targeting  
The positive charge of the DNA nanoparticle prevents its diffusion across the cellular 
membrane of the hepatocyte. Therefore, galactose residues were added onto the peptide in order 
to target the asialoglycoprotein receptor (ASGP-R) present on the hepatocyte.4 Targeting the 
ASGP-R facilitated entry of the DNA nanoparticle into the hepatocyte.4 
 
Secondary targeting 
Upon entry into the hepatocyte, the DNA nanoparticle is immediately trafficked into the 
endosome before being delivered to the lysosome for metabolism.4 To avoid this automatic 
degradation, histidine residues present on the nanoparticle acted to buffer the endosomal pH. This 
increased the acidity of the endosome, consequently encouraging the osmosis of water across the 
endosomal membrane.4 The endosome started to swell and eventually burst, allowing the 
nanoparticle to undergo endosomal escape and be released back into the cytosol.4  
 
Tertiary targeting 
Nuclear pore complexes (NPCs) perforate the nuclear envelope, thereby determining which 
particles are allowed to pass between the cytosol and the nucleus. Due to the large size of the DNA 
nanoparticle, NPCs prevent its entry from the cytosol into the nucleus.4 Therefore, a nuclear 
localizing sequence (NLS) was installed onto the nanoparticle to encourage interaction with the 
NPCs.4 This allowed the nanoparticle to enter the nucleus and carry out DNA transcription.  
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CHAPTER 1: USE OF CLOFIBRATE TO BYPASS NUCLEAR TARGETING 
 
Introduction 
Clofibrate is a commercially available drug that was intended for use in humans to control 
high cholesterol and triacylglyeride levels.5 However, a study in 1965 revealed that clofibrate 
caused hepatomegaly in rodents and the drug was withdrawn from the market.6 Over the next 
several years, numerous clinical trials were done to investigate differences in response between 
rodents and primates. These studies found that primates have less peroxisome proliferation 
compared to rodents and hepatomegaly is consequently not observed.7 
Previous experiments in our lab have investigated the use of clofibrate in non-viral delivery 
systems.8 Because of its mitogenic effects, clofibrate could potentially be used to bypass the need 
for nuclear targeting. Diffusion of the DNA nanoparticle through dividing hepatocytes would 
allow for re-formation of the nuclear envelope around the nanoparticle, essentially delivering the 
genetic material into the nucleus without having to install nuclear targeting sequences onto the 
peptide. These experiments showed a significant increase in gene expression when using non-
targeted DNA nanoparticles.8 However, no significant increase was observed with primary-
targeted DNA nanoparticles.8  
We decided to replicate this experiment, with the possibility of seeing more gene 
expression by using targeted DNA nanoparticles that now contained additional secondary and 
tertiary targeting. We hypothesized that these fully targeted DNA nanoparticles will exhibit 
increased gene expression in hepatocytes compared to non-targeted DNA nanoparticles. 
 
Materials and Methods 
Animal model. Twelve, 20 g ICR male mice were purchased from Envigo Labs. The mice 
were assigned to one of four treatment groups, with each group containing three mice (n = 3) that 
were dosed with the designated treatment protocol (Figure 1-1).  
Dosing clofibrate. Clofibrate (Sigma-Aldrich, St. Louis, MO), with a density of 1.14 
mg/l, was dissolved in corn oil (Sigma-Aldrich, St. Louis, MO) prior to dosing. Mice were 
weighed and dosed at 500 mg/kg in a 200 l intraperitoneal (IP) injection of corn oil with or 
without the presence of clofibrate. Mice were dosed daily for five days. Mice were weighed every 
day.  
Dosing the DNA nanoparticle. Previously synthesized non-targeted and targeted peptides 
were obtained from the lab. Non-targeted peptides lacked targeting specific for hepatocytes. 
Targeted peptides contained primary, secondary, and tertiary targeting for hepatocytes. In order to 
form the DNA nanoparticle, 0.4 nmol of the peptide underwent heat shrinking at 100C for 10 
minutes before being complexed with 10 g CMV promoted luciferase plasmid DNA (gWiz Luc) 
obtained from Alta Biotech Labs. Only mice from Treatment Group III and Treatment Group IV 
were dosed with the non-targeted or targeted DNA nanoparticle on Day 4 via intravenous (IV) 
injection of their tail vein. 
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Treatment Group Dosing Protocol 
Group I 1. Corn oil IP injection 
Group II 1. Clofibrate in corn oil IP injection 
Group III 1. Clofibrate in corn oil IP injection 
2. Non-targeted DNA nanoparticle IV 
injection 
Group IV 1. Clofibrate in corn oil IP injection 
2. Targeted DNA nanoparticle IV injection 
Measuring gene expression. Mice were imaged for bioluminescence activity on Day 5 and 
Day 8 to determine gene expression from non-targeted and targeted DNA nanoparticles. Mice were 
sacrificed on Day 8 and their livers were weighed to confirm mitogen activity in the mice that 
received clofibrate. Statistically significance was determined by t-test or one-way analysis of 
variance (ANOVA) with Dunnet’s Multiple Comparisons Test on GraphPad Prism. A p-value < 
0.05 between treatment groups was to be considered statistically significant. 
 
Results 
  Body weight gain. No significant difference in body weight gain of the mice was seen 
across treatment groups over the course of the 5-day dosing period (Figure 1-2). In the previously 
performed experiments in our lab, clofibrate also did not significantly affect the overall weight of 
the mice.8  
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Figure 1-1.  Treatment protocols of each treatment group used in the experiment. Corn oil with or 
without the presence of clofibrate was dosed intraperitoneally (IP). DNA nanoparticles were dosed 
intravenously (IV). Each treatment group contained three mice (n = 3).   
Figure 1-2. Mice were weighed every day and the average body weight was obtained from each 
treatment group (n = 3). No significant difference in body weight was observed across treatment groups 
after GraphPad Prism ANOVA analysis (p = 0.8791 for G-I vs. G-II; p = 0.9817 for G-I vs. G-III; p = 
0.4834 for G-I vs. G-IV).  
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Liver weight gain. No significant difference in liver weight gain of the mice was seen across 
treatment groups (Figure 1-3). Given the mitogenic effects of clofibrate, mice were expected to 
exhibit hepatomegaly over the course of the dosing period.8 
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Despite no significant difference in liver weight gain, visual inspection of the livers did reveal 
hepatomegaly in the mice that received clofibrate compared to corn oil only (Figure 1-4). Previous 
experiments also indicated a difference in liver appearance upon visual inspection.8 
 
 
 
 Gene expression. Compared to the corn oil only control group, mice that received the non-
targeted DNA nanoparticle dosed in clofibrate had a 10-fold increase in luciferase gene expression 
Figure 1-3. Mice were sacrificed and livers were surgically removed and weighed. Liver weights were 
obtained from all mice and the average liver weight was determined from each treatment group (n = 3). 
Groups II, III, and IV were dosed with the liver mitogen, clofibrate. No significant difference in liver 
weight was seen across treatment groups (p = 0.7031 for G-I vs. G-II; p = 0.8555 for G-I vs. G-III; p = 
0.2469 for G-I vs. G-IV).  
Figure 1-4. Livers of mice were inspected for differences in physical appearance across treatment 
groups. Group I received corn oil and Groups II, III, and IV received clofibrate. 
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(Figure 1-5). This result was statistically significant. However, as seen in previous experiments, 
no significant different was seen in gene expression across the remaining experimental groups.8 
G
ro
u
p
 I
G
ro
u
p
 I
I
G
ro
u
p
 I
I I
G
ro
u
p
 I
V
1 0 4
1 0 5
1 0 6
1 0 7
L u c ife ra s e  A c t iv ity  o f M ic e
B
L
I 
U
n
it
s
*
 
 
Discussion 
 This experiment was done to reproduce results from a previous experiment done in the lab 
that suggested the use of clofibrate to bypass the need for nuclear targeting in non-viral delivery 
systems.8 Because previous results counterintuitively showed a significant increase in gene 
expression from non-targeted DNA nanoparticles, but not targeted DNA nanoparticles, we 
hypothesized that gene expression would increase with DNA nanoparticles that contained 
additional targeting for mice hepatocytes.  
 Over the course of the five-day dosing period, no significant body weight gain was seen 
across the treatment groups. This was expected because clofibrate only induces mitogenic activity 
in the liver, rather than all cells within the body.6 In addition, no significant body weight gain was 
observed in the previously performed clofibrate experiments in our lab.8 
No significant liver weight gain was seen across treatment groups that were dosed with 
clofibrate. Since clofibrate is a liver mitogen, we expected to observe significant liver weight gain 
in the mice that received clofibrate compared to the mice that received corn oil only.5 A dosing 
protocol of 500 mg/kg has been shown to increase liver weight gain in experiments done in our 
lab as well as across literature data investigating the effects of clofibrate on liver metabolism.8 
Although there was no significant weight gain, visual inspection of the livers from all clofibrate-
treatment groups appeared to exhibit hepatomegaly. 
Despite the addition of more targeting, targeted DNA nanoparticles did not show a 
significant increase in luciferase gene expression. Instead, only non-targeted DNA nanoparticles 
exhibited a statistically significant increase, with a 10-fold increase in gene expression in the non-
targeted group compared to the control group. This indicates that more DNA was delivered to the 
nuclei of hepatocytes in the presence of clofibrate when using non-targeted DNA nanoparticles 
compared to targeted DNA nanoparticles. Increased gene expression from non-targeted DNA 
Figure 1-5. Group III mice (clofibrate + non-targeted DNA) had a statistically significant increase in 
luciferase gene expression compared to Group I mice (corn oil only) (p = 0.9763 for G-I vs. G-II; p = 
0.0108 for G-I vs. G-III; p = 0.5620 for G-I vs. G-IV). 
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nanoparticles compared to targeted DNA experiments was also observed in previous experiments 
in our lab.8  
A significant limitation to this experiment was the design of the targeted DNA 
nanoparticle. We have found that these targeted peptides, despite the installation of additional 
targeting, do not bind well to DNA during nanoparticle formation. Therefore, due to its bulky 
structure, limited amounts of the DNA nanoparticle are able to enter the nuclei of hepatocytes. 
Further experiments are currently being done to improve DNA binding efficiency to these targeted 
peptides.  
In conclusion, non-targeted DNA nanoparticles exhibited significantly more gene 
expression compared to targeted DNA nanoparticles in mice hepatocytes when dosed in the 
presence of clofibrate. Despite increased gene expression, there was no significant increase in mice 
liver weight over the course of the experiment. Considering gene expression was higher in non-
targeted DNA nanoparticles, further experiments should be performed to determine if non-targeted 
nanoparticles exhibit a dose-dependent response in hepatocyte gene expression when in the 
presence of clofibrate.  
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CHAPTER 2: DOSE-DEPENDENT RESPONSIVENESS OF NON-TARGETED DNA 
NANOPARTICLES IN THE PRESENCE OF CLOFIBRATE 
 
Introduction 
 Recent experiments on the use of clofibrate to bypass the need for nuclear targeting found 
that luciferase gene expression was greater in non-targeted DNA nanoparticles. Therefore, we 
wanted to determine if these nanoparticles were able to exhibit a dose-dependent response in gene 
delivery to hepatocytes. If a dose-dependent response is observed, this could support the use of 
non-targeted DNA nanoparticles in non-viral gene delivery systems. 
 In addition, no significant increase in liver weight gain was observed in mice dosed with 
clofibrate. Since the literature typically utilizes a 14-day dosing protocol to induce hepatomegaly 
in rodents, we decided to modify our original clofibrate dosing protocol for this experiment.9   
 Due to non-targeted DNA nanoparticles exhibiting increased gene expression, we 
hypothesized that a dose-dependent response would be seen in mice hepatocytes. In addition, we 
hypothesized that when dosed with clofibrate over a 14-day protocol, a significant weight gain 
would be observed in the livers of mice. 
 
Materials and Methods 
 Animal mode. Nine, 20 g ICR male mice were purchased from Envigo Labs. The mice 
were assigned to one of three treatment groups. Each group contained three mice (n = 3) that were 
dosed with the designated treatment protocol (Figure 2-1).  
Dosing clofibrate. Clofibrate (Sigma-Aldrich, St. Louis, MO), with a density of 1.14 
mg/l, was dissolved in corn oil (Sigma-Aldrich, St. Louis, MO) prior to dosing. Mice were 
weighed and all mice were dosed at 500 mg/kg in a 200 l intraperitoneal (IP) injection of corn 
oil with clofibrate. Mice were dosed daily for 14 days. Mice were weighed every day.  
Dosing the DNA nanoparticle. Previously synthesized non-targeted peptides were obtained 
from the lab. The peptides were to be complexed with either 10 g or 100 g gWizLuc (Figure 2-
1). First, gWizLuc underwent heat shrinking at 100C for 10 minutes. Then, 0.4 nmol of non-
targeted peptide was added to the heated plasmid, forming the DNA nanoparticle. All treatment 
groups were dosed with clofibrate. Only Treatment Group II and Treatment Group III were dosed 
with the non-targeted DNA nanoparticle on Day 12 via intravenous (IV) injection of their tail vein. 
 
Treatment Group Dosing Protocol 
Group I 1. Clofibrate in corn oil IP injection 
Group II 1. Clofibrate in corn oil IP injection 
2. Non-targeted DNA nanoparticle 
containing 10 ug gWiz Luc IV injection 
Group III 1. Clofibrate in corn oil IP injection 
2. Non-targeted DNA nanoparticle 
containing 100 ug gWiz Luc IV injection 
 
Measuring gene expression. Mice were imaged for bioluminescence activity on Day 14 to 
determine gene expression. Mice were sacrificed and their livers were weighed to confirm mitogen 
Figure 2-1.  Treatment protocols of each treatment group used in the experiment. Corn oil in clofibrate 
was dosed intraperitoneally (IP). DNA nanoparticles were dosed intravenously (IV). Each treatment 
group contained three mice (n = 3). 
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activity of hepatocytes via visual inspection. Statistically significant differences were determined 
by t-test or one-way analysis of variance (ANOVA) with Dunnet’s Multiple Comparisons Test on 
GraphPad Prism. A p-value < 0.05 between treatment groups was to be considered statistically 
significant. 
 
Results 
Body weight gain. No significant difference in body weight gain was seen across treatment 
groups over the course of the 14-day dosing period (Figure 2-2). Previously performed 
experiments also did not see a significant increase in weight gain.8 
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Liver weight gain. No significant difference in liver weight gain was seen across treatment 
groups (Figure 2-3). Mice were expected to have an increase in liver weight over duration of the 
longer dosing period based on literature data.9 
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Figure 2-2. Mice were weighed every day and the average body weight was obtained from each 
treatment group (n = 3). No significant changes in body weight was observed after GraphPad Prism 
ANOVA analysis (p = 0.9833 for G-I vs. G-II; p = 0.9996 for G-I vs. G-III).  
Figure 2-3. Mice were sacrificed and livers were surgically removed and weighed. Liver weights were 
obtained from all mice and the average liver weight was determined from each treatment group (n = 3). 
All treatment groups received the liver mitogen, clofibrate. No significant difference in liver weight was 
seen across treatment groups (p = 0.9089 from G-I vs. G-II; p = 0.9976 for G-I vs. G-III).  
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Despite no significant difference in weight gain, visual inspection of the livers did reveal 
hepatomegaly in all mice (Figure 2-4). Appearance of hepatomegaly from visual inspection is 
consistently seen across previous experiments performed in our lab.8 
 
 
Gene Expression. No significant difference in luciferase gene expression was observed 
across all treatment groups (Figure 2-5). This result contradicts previous experiments, where mice 
that received non-targeted DNA nanoparticles (Groups II and III) displayed a significant increase 
in gene expression compared to the control group (Group I).8 
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Discussion 
 This experiment was done to determine if non-targeted DNA nanoparticles displayed a 
dose-dependent response in luciferase gene expression. If a dose-dependent response was seen, 
Figure 2-4. Livers of mice were inspected for differences in physical appearance across treatment 
groups. Groups I, II, and III all received the clofibrate dissolved in corn oil for a duration of 14 days. 
Figure 2-5. Group I treatment group mice received clofibrate only. Groups II and III treatment group 
mice received 10 g and 100 g respectively of gWiz Luc plasmid complexed to non-targeted DNA 
nanoparticles. No statistically significant difference in gene expression was seen across treatment 
groups (p = 0.3672 for G-I vs. G-II; p = 0.9771 for G-I vs. G-III). 
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non-targeted DNA nanoparticles could potentially be implemented in non-viral delivery of DNA 
to the hepatocytes of mice. 
 No significant increase in the body weight of the mice was observed across treatment 
groups. This result is supported by previous experiments as well.6,8  
 No significant increase in liver weight was seen in the mice, however visual inspection of 
the livers did reveal apparent hepatomegaly. With a 500 mg/kg dosing protocol over the duration 
of 14 days, we expected to see an increase in liver weight based on literature data.6,8  
 Despite previous experiments showing increased gene expression from non-targeted DNA 
nanoparticles, no significant increase in expression was seen in this experiment.8 This contradicted 
what was expected, because the Group II mice received the same 10 g dose of gWizLuc shown 
in previous experiments to increase gene expression.8 In addition, the Group III mice received a 
higher, 100 g dose of gWizLuc but also displayed no significant increase in expression. 
Therefore, due to the lack of a dose-dependent response, non-targeted DNA nanoparticles cannot 
be relied upon to induce consistent increases in gene expression from mice hepatocytes dosed with 
clofibrate. 
 One limitation was in the experimental modification that had to be used. Given the small 
size of mice, the IV dose of the DNA nanoparticle must be limited to 200 l in total volume. 
Therefore, less buffer and water had to be used than usual for a 100 g dose of DNA. As a result, 
this may have affected the structure of the DNA as well as the ability of DNA to bind to the peptide 
when forming the non-targeted DNA nanoparticle. Another possible limitation was due to the 
mitogenic effects of clofibrate on the mice hepatocytes. Since no significant increase in liver 
weight was seen consistently across both experiments, it is possible that not enough clofibrate was 
delivered to hepatocytes in order to induce mitogenic activity. This would have affected liver 
weight gain as well as limited the ability of the DNA nanoparticle to enter the nucleus of dividing 
hepatocytes. 
In conclusion, because non-targeted DNA nanoparticles lack a dose-dependent response, 
it cannot be determined that clofibrate can be used to bypass the need for nuclear targeting in 
non-viral gene delivery systems. Therefore, it was decided that the use of clofibrate would not be 
further explored in the development of a non-viral gene delivery system.  
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